ANI Pharmaceuticals CEO Arthur Przybyl leaves

  • Push-out Score determined
  • After around 11 years in the position
  • Praise, thanks and good wishes for Przybyl
  • Search for a successor
  • Przybyl spoke at length and said 138 words

(exechange) — Baudette, Minnesota, April 14, 2020 — Arthur Przybyl, chief executive of ANI Pharmaceuticals, leaves. As announced by ANI Pharmaceuticals Inc. in a news release on Tuesday, April 14, 2020, Arthur S. Przybyl leaves his post as chief executive officer at the integrated specialty pharmaceutical company after around 11 years in the role, effective May 10, 2020.

ANI Pharmaceuticals will undertake a search for a successor.

“The time is right”

Arthur Przybyl’s departure from the CEO post is explained as follows. Przybyl said: “After 11 years as President and CEO of ANI, the Board and I have determined that the time is right to transition to new leadership as the Company prepares to launch Cortrophin® Gel and expand its portfolio of specialty pharmaceutical products.”

Precise information regarding Arthur Przybyl’s future plans was not immediately available.


ANI Pharmaceuticals said: “Arthur S. Przybyl will depart as President and Chief Executive Officer on May 10, 2020.”

Share price decline

The announcement follows a decline in ANI Pharmaceuticals Inc.’s share price of 29% since April 2019.

Chaired by Robert E. Brown, Jr.

ANI Pharmaceuticals Inc. is chaired by Robert E. Brown, Jr.

Robert E. Brown, Jr. has served as a director of the Company and Chairman of the Board since June 2013 and had served as a director of the Company’s operating subsidiary, ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. (“ANIP”) since July 2010.

In the position of CEO since 2009

Arthur Przybyl became CEO of the Company in 2009.

Arthur S. Przybyl has served as a director, President, and Chief Executive Officer of the Company since June 2013 and had joined ANIP in March 2009 as President and Chief Executive Officer.

Przybyl is an experienced healthcare executive in a career that spans over 25 years and includes the management of both specialty pharmaceutical and medical device companies.

From August 2002 through January 2009, Przybyl served as President and Chief Executive Officer of Akorn, Inc., a NASDAQ-listed specialty pharmaceutical company that manufactures and markets ophthalmic, liquid and lyophilized injectable, and vaccine drug products.

Prior to Akorn, Przybyl was President of privately-held company Hearing Innovations, Inc. and President and Chief Operating Officer of NASDAQ-listed company Bioject, Inc., both of which are medical device companies.

During his career, Przybyl has held several sales and marketing management positions, including Senior Vice President, Sales and Marketing for International Medication Systems, Inc. and Director, Corporate Marketing and National Accounts for LyphoMed, Inc., both specialty pharmaceutical companies.

Push-out Score determined

The Push-out Score™ determined by exechange gauges the pressure surrounding the management change on a scale of 0 to 10.

Read the full story in the exechange report 16.2020 ($).